AdvanCell
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.
$315MSeries D
Role not disclosedS
SymBiosis
Activity from announced rounds
Activity in this selectionOct 25, 2026 · Healthtech · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $315M 1 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionCorxel Pharmaceuticals
Corxel Pharmaceuticals develops clinical-stage medicines for cardiometabolic diseases, including obesity, diabetes, stroke and hypertension.
≤$287MSeries D1
Participant